Immune thrombocytopenia in children: the immune character of destructive thrombocytopenia and the treatment of bleeding.
It is now recognized that different forms of destructive thrombocytopenia due to antibody binding to platelets exist, which can be differentiated by sensitive new assays. Thus, the name has been changed from idiopathic to immune thrombocytopenic purpura (ITP). The immune character of ITP has been further supported by the success of treatment with human antibody concentrate-immunoglobulin treatment. During different studies of ITP in children, it has been recognized that only patients with bleeding in addition to a platelet count less than 20 x 10(9)/L need to be treated. The various forms of treatment are reviewed.
Imbach
P
P
Children's Hospital Aarau and Basle, University of Basle, Switzerland.
D002648:Child; D002675:Child, Preschool; D006470:Hemorrhage / Q000628:therapy*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D010976:Platelet Count; D011696:Purpura, Thrombocytopenic / Q000276:immunology* / Q000503:physiopathology / Q000628:therapy*